There are five WHO Collaborating Centres working for pharmacovigilance, each in specialist areas. In addition to UMC in Sweden, these are in India, Morocco, the Netherlands, and Norway.
The Rabat centre assists WHO by building capacity in the WHO Eastern Mediterranean Region, in francophone, and Arabic countries.
The centre in Rabat – Centre Anti Poison et de Pharmacovigilance du Maroc – became a WHO Collaborating Centre in 2011. It facilitates regional and national training courses and supports initiatives to promote patient safety in this geographical area. Its annual francophone training course covers topics such as patient safety, VigiFlow, causality assessment, pharmacovigilance of herbal medicines, vaccines, and medication errors.
The Rabat centre is involved in projects integrating patient safety reporting systems across different types of health facilities, and pharmacovigilance in public health programmes such as those for multi-drug resistant tuberculosis. The Centre supports WHO in developing pharmacovigilance guidelines, tools and methods to detect and minimise medication errors. It also surveys and evaluates performance and development of pharmacovigilance systems in Africa.
Run by the Netherlands national pharmacovigilance centre (Pharmacovigilance Centre Lareb), it became a WHO Collaborating Centre in 2013. This centre specialises in the processing and scientific evaluation of patient reporting.
Its role is to assist WHO in training member countries on how to stimulate and manage patient reports. It holds workshops and hosts visitors at the Centre to share their experiences of patient reporting, and support is provided through information and feedback.
The Centre conducts research on the contribution of patient reports to pharmacovigilance, conducted in collaboration with the University of Groningen. Further to the work involving patient reports, the Centre promotes pharmacovigilance education in colleges and universities by developing and maintaining a curriculum for medical, pharmacy and paramedical students. A project collecting information on the content of a core pharmacovigilance curriculum is in progress. The Centre will be organising workshops for member countries of the WHO Programme to discuss this curriculum.
The Centre in Norway was established in 1982 in Oslo at the Department of Pharmacoepidemiology at the Norwegian Institute of Public Health, funded by the Norwegian Government.
The Centre's main activities are the development and maintenance of the Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) system. Their priorities include:
Founded in 2010, the Pharmacovigilance Programme of India (PvPI) was designated as a specialist centre by WHO in Geneva, 2017.